Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Radiat Oncol Biol Phys ; 23(3): 533-7, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1612953

RESUMO

A retrospective study was done of 338 patients with pterygia treated between October 1974 and May 1990. These patients resided in the desert of the southwestern United States, where the hot, dry, dusty climate is thought to predispose to pterygium formation and subsequent recurrence. The pterygia were excised, and the administration of beta irradiation was initiated within 24 hr of surgery. Sixteen percent of the pterygia were recurrent. Ninety-five percent of the beta irradiation prescriptions consisted of 3 weekly 800 cGy fractions. For patients with a minimum of 6 months follow-up, the crude local control rate was 225/258 (88%). The Kaplan-Meier estimate of the 5-year local control rate was 84% (95% confidence interval: 79-89%). Ten of 33 recurrences were diagnosed within 6 months, and 32/33 recurrences were diagnosed within 5 years of treatment. Previously untreated pterygia were controlled more easily than were recurrent pterygia (p = 0.005). In 86% of the cases, patients judged the cosmetic results to be satisfactory. No severe complications developed. This study and others, when compared with studies involving excision alone, suggest that postoperative beta irradiation reduces the likelihood for pterygium recurrence. When the beta irradiation is fractionated, satisfactory cosmetic results can be achieved with low morbidity.


Assuntos
Partículas beta/uso terapêutico , Pterígio/terapia , Radioisótopos de Estrôncio/uso terapêutico , Adulto , Idoso , Catarata/etiologia , Terapia Combinada , Humanos , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Recidiva
2.
Arch Dermatol ; 127(11): 1668-72, 1991 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-1952970

RESUMO

A retrospective study was performed of 61 recurrent basal cell carcinomas treated with radiation therapy between 1974 and 1990 at the University of Arizona College of Medicine or at Southwestern Radiation Oncology, Tucson, Arizona. The median length of follow-up was 57 months. Applying the American Joint Committee on Cancer staging system to these recurrent tumors, 36 were stage I, 19 were stage II, five were stage III, and one was stage IV. Kaplan-Meier methods were used to estimate the 5-year complete remission rates. The Mantel-Haenszel Test and the Cox Proportional Hazards Model were used to determine if tumor size, stage, histologic subtype, anatomic site, age, sex, dose, number of radiation therapy treatments, length of time over which the radiation therapy was administered, or type of radiation beam used (orthovoltage x-rays vs megavoltage electrons) affected the 5-year complete remission rates. Only tumor size and stage had a statistically significant effect on the complete remission rates. The Kaplan-Meier estimates of the 5-year complete remission rates for 0.5- to 1.0-cm tumors vs tumors larger than 1.0 cm were 96% (95% confidence interval, 88% to 100%) and 81% (95% confidence interval, 64% to 99%), respectively. The Kaplan-Meier estimates of the 5-year complete remission rates for stage I/II tumors vs stage III/IV tumors were 93% (95% confidence interval, 85% to 100%) and 42% (95% confidence interval, 8% to 84%), respectively. Functional and cosmetic results were frequently good to excellent at 5 years. Soft-tissue necrosis developed in two of 61 cases, and was successfully managed in both. This article, combined with a review of the literature, suggests that radiation therapy is an effective method of treating recurrent basal cell carcinomas.


Assuntos
Carcinoma Basocelular/radioterapia , Recidiva Local de Neoplasia/radioterapia , Neoplasias Cutâneas/radioterapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Basocelular/patologia , Seguimentos , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Radioterapia/efeitos adversos , Estudos Retrospectivos , Neoplasias Cutâneas/patologia
4.
Obstet Gynecol ; 52(1): 97-9, 1978 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-567310

RESUMO

An analysis of 41 patients with histologically documented Stage II adenocarcinoma of the endometrium treated between 1969 and 1974 is presented. The 3-year survival for all patients was 46%. Patients treated with radiation therapy alone (tandem, ovoids, and external radiation therapy) had 29% survival while patients treated with radiation therapy and surgery had a 71% survival. For all patients, survival by grade was 80% (Grade I), 36% (Grade II), and 20% (Grade III). Among those patients with recurrent disease, 40% of cases were in the pelvis while 20% were isolated distal recurrences. Patients with stromal invasion of the cervix had a 30% survival while patients without stromal invasion had a 67% survival. An analysis of these data, along with a review of the literature, reveals that 1) hysterectomy plays a critical role in survival, 2) invasion of the cervical stroma would appear to be a requisite criteria for the establishment of Stage II disease, and 3) aggressive radiation therapy with uterine packings (Heyman capsules) should be attempted in those patients who are not surgical candidates.


Assuntos
Adenocarcinoma/terapia , Neoplasias Uterinas/terapia , Adenocarcinoma/patologia , Adenocarcinoma/radioterapia , Adenocarcinoma/cirurgia , Castração , Tubas Uterinas/cirurgia , Feminino , Humanos , Histerectomia , Neoplasias Uterinas/patologia , Neoplasias Uterinas/radioterapia , Neoplasias Uterinas/cirurgia
5.
Radiology ; 114(1): 225-6, 1975 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1208864

RESUMO

Previous work has shown that radioactive colloids can cure Ehrlich ascites tumor. In this experiment, the dose of colloidal 198Au needed has been correlated with the number of tumor cells inoculated. On Day 1, varying numbers of Ehrlich cells (10(2), 10(3), 10(4), 10(5), 10(6)) were injected intraperitoneally into 310 BALB/c male mice. Two hours later, varying doses (10, 20, 40, 80, and 160 muCi) of 198Au were injected intraperitoneally. Controls were injected with normal saline. Generally, the lower cell inoculums and higher doses of 198Au yielded better survival rates.


Assuntos
Carcinoma de Ehrlich/prevenção & controle , Ouro Coloide Radioativo/uso terapêutico , Animais , Carcinoma de Ehrlich/patologia , Relação Dose-Resposta a Droga , Ouro Coloide Radioativo/administração & dosagem , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...